Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?

Abstract :

During advanced vasodilatory shock, arginine vasopressin (AVP) is increasingly used to restore blood pressure and thus to reduce catecholamine requirements. The AVP-related rise in mean arterial pressure is due to systemic vasoconstriction, which, depending on the infusion rate, may also reduce coronary blood flow despite an increased coronary perfusion pressure. In a murine model of myocardial ischaemia, Indrambarya and colleagues now report that a 3-day infusion of AVP decreased the left ventricular ejection fraction, ultimately resulting in increased mortality, and thus compared unfavourably with a standard treatment using dobutamine. The AVP-related impairment myocardial dysfunction did not result from the increased left ventricular afterload but from a direct effect on cardiac contractility. Consequently, the authors conclude that the use of AVP should be cautioned in patients with underlying cardiac disease.

Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Okina Univ Angers Connectez-vous pour contacter le contributeur
Soumis le : mardi 22 juin 2021 - 14:53:14
Dernière modification le : jeudi 20 janvier 2022 - 12:18:02

Lien texte intégral




Pierre Asfar, Peter Radermacher. Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?. Critical Care, BioMed Central, 2009, 13 (4), pp.1 - 3. ⟨10.1186/cc7954⟩. ⟨hal-03267475⟩



Consultations de la notice